Physician profile
Amy Chung
NPI 1376987057
$2,407.58
in general payments reported to CMS, 2019-2025
23 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.66 · 2020: $34.11 · 2021: $91.13 · 2022: $50.15 · 2023: $71.89 · 2024: $860 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.24 | 2021-2025 | Qulipta |
| Novo Nordisk INC | $273.28 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $220.50 | 2024-2025 | |
| Lilly USA, LLC | $213.01 | 2021-2025 | Zepbound, Mounjaro, Kisunla |
| Glaxosmithkline, LLC. | $208.36 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $187.10 | 2024-2025 | |
| Amgen INC. | $121.78 | 2019-2025 | Evenity, Otezla, Repatha |
| Dexcom, INC. | $82.33 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $80.18 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $77.79 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $75.88 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.35 | 2024-2025 | Xifaxan, Trulance |
| Abiomed | $51.78 | 2025 | |
| Medtronic, INC. | $51.03 | 2021-2025 | Symplicity G3, Inceptiv |
| Radius Health, INC. | $44.59 | 2024-2025 | Tymlos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.82 | 2024-2025 | |
| Edwards Lifesciences Corporation | $30.55 | 2025 | Sapien 3 Ultra Resilia |
| Acella Pharmaceuticals, LLC | $30.01 | 2025 | NP Thyroid 60 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.73 | 2024-2025 | Jardiance |
| Abbott Laboratories | $27.28 | 2025 | Freestyle Libre 3 |
| Eisai INC. | $21.93 | 2024 | |
| Sanofi-Aventis U.S. LLC | $19.91 | 2024 | |
| Vanda Pharmaceuticals INC. | $18.15 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.